News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dako A/S and Amgen (AMGN) to Collaborate in Development of a Companion Diagnostic for an Amgen Investigational Cancer Therapy



1/10/2012 8:23:11 AM

Dako, a world leading independent cancer diagnostic supplier with 45 years of experience in pathology, announced today that it has entered into a development and collaboration agreement with Amgen Inc. (Nasdaq: AMGN) to develop a diagnostic test for an Amgen cancer drug candidate targeted for a rare and deadly cancer. "I am proud to announce that Dako and Amgen have succeeded in putting together a business model that supports the concurrent development of drug and diagnostics for a low incidence cancer - something that has been difficult to achieve in the industry until now," says Lars Holmkvist, Dako's chief executive officer.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES